日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non-Small Cell Lung Cancer

基于深度学习的连续CT扫描预测免疫疗法治疗的非小细胞肺癌患者的生存期

Sako, Chiharu; Kurland, Brenda F; Schmidt, Taly G; He, Jing; De Groot, Marius; Patel, Arpan A; Owen, Dwight H; Amini, Arya; Curti, Brendan D; Kelly, Ronan J; Page, Ray D; Swalduz, Aurelie; Beregi, Jean-Paul; Chrusciel, Jan; Sanchez, Stephane; Weiss, Jakob; Liu, An; Gevaert, Olivier; Hart, Alma; Simon, George R; Parikh, Ravi B; van der Aart, Jasper; Jordan, Petr

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

达拉非尼联合曲美替尼对比纳武利尤单抗联合伊匹木单抗治疗晚期BRAF突变型黑色素瘤患者:DREAMseq试验-ECOG-ACRIN EA6134

Atkins, Michael B; Lee, Sandra J; Chmielowski, Bartosz; Tarhini, Ahmad A; Cohen, Gary I; Truong, Thach-Giao; Moon, Helen H; Davar, Diwakar; O'Rourke, Mark; Stephenson, Joseph J; Curti, Brendan D; Urba, Walter J; Brell, Joanna M; Funchain, Pauline; Kendra, Kari L; Ikeguchi, Alexandra P; Jaslowski, Anthony; Bane, Charles L; Taylor, Mark A; Bajaj, Madhuri; Conry, Robert M; Ellis, Robert J; Logan, Theodore F; Laudi, Noel; Sosman, Jeffrey A; Crockett, David G; Pecora, Andrew L; Okazaki, Ian J; Reganti, Sowjanya; Chandra, Sunandana; Guild, Samantha; Chen, Helen X; Streicher, Howard Z; Wolchok, Jedd D; Ribas, Antoni; Kirkwood, John M

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

贝培加地白介素联合纳武利尤单抗治疗未经治疗的晚期黑色素瘤:开放标签、III期PIVOT IO 001试验结果

Diab, Adi; Gogas, Helen; Sandhu, Shahneen; Long, Georgina V; Ascierto, Paolo A; Larkin, James; Sznol, Mario; Franke, Fabio; Ciuleanu, Tudor E; Pereira, Caio; Muñoz Couselo, Eva; Bronzon Damian, Fernanda; Schenker, Michael; Perfetti, Aldo; Lebbe, Celeste; Quéreux, Gaëlle; Meier, Friedegund; Curti, Brendan D; Rojas, Carlos; Arriaga, Yull; Yang, Haisu; Zhou, Ming; Ravimohan, Shruthi; Statkevich, Paul; Tagliaferri, Mary A; Khushalani, Nikhil I

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

一项针对晚期实体瘤患者的静脉注射柯萨奇病毒A21(V937)联合或不联合帕博利珠单抗的安全性、药代动力学和初步疗效的1期开放标签剂量递增研究

Rudin, Charles M; Pandha, Hardev S; Zibelman, Matthew; Akerley, Wallace L; Harrington, Kevin J; Day, Daphne; Hill, Andrew G; O'Day, Steven J; Clay, Timothy D; Wright, Gavin M; Jennens, Ross R; Gerber, David E; Rosenberg, Jonathan E; Ralph, Christy; Campbell, David C; Curti, Brendan D; Merchan, Jaime R; Ren, Yixin; Schmidt, Emmett V; Guttman, Lisa; Gupta, Sumati

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas

SEA-CD40(一种非岩藻糖基化的CD40激动剂)在晚期实体瘤和淋巴瘤中的I期剂量递增研究

Coveler, Andrew L; Smith, David C; Phillips, Tycel; Curti, Brendan D; Goel, Sanjay; Mehta, Amitkumar N; Kuzel, Timothy M; Markovic, Svetomir N; Rixe, Olivier; Bajor, David L; Gajewski, Thomas F; Gutierrez, Martin; Lee, Hun Ju; Gopal, Ajay K; Caimi, Paolo; Heath, Elisabeth I; Thompson, John A; Ansari, Sahar; Jacquemont, Celine; Topletz-Erickson, Ariel; Zhou, Peigen; Schmitt, Michael W; Grilley-Olson, Juneko E

Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies

癌症的暗物质:揭开深渊,展现全新疗法的宇宙

Fox, Bernard A; Urba, Walter J; Jensen, Shawn M; Page, David B; Curti, Brendan D; Sanborn, Rachel E; Leidner, Rom S

Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609

在 III 期试验 E1609 中,接受辅助治疗的 III-IV 期高危黑色素瘤患者报告的伊匹木单抗(3 或 10 mg/kg)与高剂量干扰素 α-2b 的耐受性比较

McLouth, Laurie E; Zheng, Yue; Smith, Stephanie; Hodi, F Stephen; Rao, Uma N; Cohen, Gary I; Amatruda, Thomas T; Dakhil, Shaker R; Curti, Brendan D; Nakhoul, Ibrahim; Chandana, Sreenivasa R; Bane, Charles L; Marinier, David E; Lee, Sandra J; Sondak, Vernon K; Kirkwood, John M; Tarhini, Ahmad A; Wagner, Lynne I

Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study

肿瘤内溶瘤病毒V937联合伊匹木单抗治疗晚期黑色素瘤患者:1b期MITCI研究

Curti, Brendan D; Richards, Jon; Hyngstrom, John R; Daniels, Gregory A; Faries, Mark; Feun, Lynn; Margolin, Kim A; Hallmeyer, Sigrun; Grose, Mark; Zhang, Yiwei; Li, Anlong; Andtbacka, Robert H I

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

Lifileucel,一种肿瘤浸润淋巴细胞疗法,用于治疗转移性黑色素瘤

Sarnaik, Amod A; Hamid, Omid; Khushalani, Nikhil I; Lewis, Karl D; Medina, Theresa; Kluger, Harriet M; Thomas, Sajeve S; Domingo-Musibay, Evidio; Pavlick, Anna C; Whitman, Eric D; Martin-Algarra, Salvador; Corrie, Pippa; Curti, Brendan D; Oláh, Judit; Lutzky, Jose; Weber, Jeffrey S; Larkin, James M G; Shi, Wen; Takamura, Toshimi; Jagasia, Madan; Qin, Harry; Wu, Xiao; Chartier, Cecile; Graf Finckenstein, Friedrich; Fardis, Maria; Kirkwood, John M; Chesney, Jason A

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

一线转移性黑色素瘤治疗:贝培加地白介素联合纳武利尤单抗

Diab, Adi; Tykodi, Scott S; Daniels, Gregory A; Maio, Michele; Curti, Brendan D; Lewis, Karl D; Jang, Sekwon; Kalinka, Ewa; Puzanov, Igor; Spira, Alexander I; Cho, Daniel C; Guan, Shanhong; Puente, Erika; Nguyen, Tuan; Hoch, Ute; Currie, Sue L; Lin, Wei; Tagliaferri, Mary A; Zalevsky, Jonathan; Sznol, Mario; Hurwitz, Michael E